Treatment of early-stage HER2+ breast cancer-an evolving field.

ABSTRACT: The evolving field of HER2-targeted therapy has significantly improved the outcome of women diagnosed with HER2-positive invasive breast cancer. In this review, we sought to summarise the efficacy of trastuzumab-based regimens in the adjuvant and neoadjuvant setting with a special emphasis on relevant clinical questions: treatment duration, sequence of trastuzumab administration, toxicity, the role of anthracycline-based regimens, and optimal management of small HER2+ tumours. Controversial topics are discussed taking into consideration the development of modern anti-HER2 agents.

SUBMITTER: Ferreira AR 

PROVIDER: S-EPMC4406526 | biostudies-literature | 2015

REPOSITORIES: biostudies-literature